Gilead Sciences’ Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire
FOSTER CITY, Calif.–(BUSINESS WIRE)–Jan. 6, 2014– Gilead Sciences, Inc. (Nasdaq:GILD) today announced that Kevin Young CBE, Executive Vice President, Commercial Operations, has informed the company of his decision to retire, effective February 4th. Mr. Young will continue to work directly with Gilead’s management team as a senior advisor.
Mr. Young joined Gilead in 2004 to lead the company’s global commercial operations. During his tenure, he oversaw the launch of eight new therapies, including the first single tablet regimen for the treatment of HIV which is now the best-selling brand-named HIV product in the United States and European Union. In addition, Mr. Young has spent the last two years preparing Gilead for the introduction of a novel oral antiviral for the treatment of chronic hepatitis C. Mr. Young also managed significant expansion of Gilead’s operations in North America, Europe and Asia, including the establishment of new affiliate offices in Poland, Russia, South Korea and Japan. Under Mr. Young’s leadership, Gilead’s annual revenues grew from $1.24 billion in 2004 to nearly $10 billion in 2012.
“Kevin’s impact on the entire Gilead organization has been tremendous, and on behalf of the company’s senior management team and board of directors, I thank him for his dedication and commitment to excellence,” said John Martin, PhD, Chairman and Chief Executive Officer, Gilead Sciences. “Over the past nine years, he has greatly expanded and strengthened our commercial organization, preparing the company to introduce products in new therapeutic areas and ensuring a consistent and clear focus on the needs of patients around the world. I have deeply valued his insights and perspectives, and look forward to a continued partnership as Kevin remains with Gilead in an advisory role.”
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North and South America, Europe and Asia Pacific.
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Source: Gilead Sciences, Inc.